Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots 

Shots:  Abbott’s AVEIR DR is the first in the world dual-chamber leadless pacemaker  Jerry Kelleher, a clinical trial participant in the AVEIR DR study, shares his transformative journey with PharmaShots  Explore Jerry’s miraculous recovery with AVEIR DR, which helped enhance his quality of life   Saurabh: Jerry, can you take us back to life and describe…
July 7, 2025

Read more

THOUGHTSPOT

Choose the Right Microplate Reader: Strategic Guide for Advanced Biologics Development

In the competitive and ever-evolving world of biologics and protein therapy, each decision can significantly influence the trajectory of your research outcomes. Among these critical choices, selecting the optimal microplate reader stands out. Far from being just another lab instrument, your choice here can dramatically shape the accuracy, efficiency, and scalability of your scientific discoveries.…
July 7, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jun 30, 2025 – Jul 04, 2025)    

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, and Biosimilar. Check out our full report below:  Neurocrine Reports Data From KINECT-HD Study Evaluating INGREZZA in Huntington’s Disease (HD)  Read More: Neurocrine  UCB Reports the P-III Data of Fenfluramine in CDKL5 Deficiency Disorder (CDD) Patients  Read More: UCB  …
July 4, 2025

Read more

THOUGHTSPOT

Is Addiction Hereditary?

When you think about addiction, you likely wonder if your family history puts you at risk. The answer isn't straightforward, genetics account for 40-60% of addiction vulnerability, while your environment shapes the rest. Your DNA influences how your brain responds to substances, but it doesn't seal your fate. Understanding this genetic component reveals why addiction…
July 4, 2025

Read more

20 Innovative Digital Therapeutics Companies of 2025
TOP 20

20 Innovative Digital Therapeutics Companies of 2025 

Shots:   The integration of innovative technologies in healthcare, such as digital health platforms and AI-enabled applications, is transforming the way diseases are detected, diagnosed, treated, and prevented  The global Digital Health market is expected to reach $197.88B in 2025 and grow at a CAGR of 6.88%, reaching $258.25B by 2029  PharmaShots presents a concise report…
July 3, 2025

Read more

VIEWPOINTS

Regeneron at ASH’24: Aafia Chaudhry in a Stimulating Dialogue Exchange with PharmaShots 

Shots:   Recently, Regeneron presented Odronextamab’s data in treating patients with different B-NHL subtypes (OLYMPIA studies) and marginal zone lymphoma (ELM-2 study)  Aafia Chaudhry, Vice President, Global Program Head for Hematology-Oncology at Regeneron, discusses Odronextamab’s ongoing studies as monotherapy and in combination to treat various malignancies  Aafia shares the upcoming PDUFA date on July 30th for…
July 2, 2025

Read more

Q1 2025
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2025 

Shots:    Q2’2025 highlights major acquisitions in the pharma and biotech industry along with collaboartion. The talk of the town remained Blueprint Medicines’ acquisition by Sanofi for ~$9.5B    The quarter highlighted Collaboartion, including Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid    PharmaShots brings the Quarterly digest compiling insights from…
July 1, 2025

Read more

VIEWPOINTS

Unlocking Approval: Christophe Piketty from Galderma in an Illuminating Conversation with PharmaShots 

Shots:   Backed by positive results from the P-III ARCADIA study, Galderma’s Nemluvio recently received approval from the US FDA for patients with moderate to severe atopic dermatitis  Nemluvio (nemolizumab) has previously been approved for the treatment of prurigo nodularis  Christophe Piketty, VP, Head of Innovation, Therapeutic Dermatology, Global Clinical Sciences, Galderma, highlighted insights from the…
June 30, 2025

Read more

10 Hidden Financial Risks Pharma Professionals Can’t Ignore
THOUGHTSPOT

10 Hidden Financial Risks Pharma Professionals Can’t Ignore

Working in the pharmaceutical industry comes with great rewards—but it’s not without its financial blind spots. High income, stock options, consulting gigs, and regulatory risk make this a unique environment where professionals can be exposed without realizing it.  If you’re focused on research, development, or clinical work, it’s easy to overlook personal finance strategy. But…
June 30, 2025

Read more

Load more